ReviewInflammopharmacology2026
Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThis narrative review provides a comprehensive update on the pathogenesis and therapeutic management of alopecia areata (AA), critically evaluating the transition from non-specific immunosuppression to targeted molecular therapies.
methodsA literature search was conducted across PubMed, Scopus, and the Cochrane Library (inception to 2024). A strict hierarchy of evidence was applied, prioritizing Phase III randomized controlled trials (RCTs) for emerging treatments while contextualizing conventional therapies within long-standing clinical practice and observational data.
resultsAA pathogenesis centers on the collapse of hair follicle immune privilege, driven by the IFN-γ/IL-15 axis. Conventional treatments (topical/intralesional corticosteroids, contact immunotherapy) remain first-line for localized disease but lack high-level evidence for extensive cases. Systemic Janus kinase (JAK) inhibitors represent a paradigm shift. Baricitinib is the first FDA-approved treatment for severe AA, supported by Level 1 evidence from the BRAVE-AA trials. Other JAK inhibitors (ritlecitinib, deuruxolitinib) show potent dose-dependent efficacy in advanced clinical phases. A critical safety appraisal highlights class-wide concerns, including upper respiratory infections and a recently identified risk of weight gain linked to leptin signaling interference. Furthermore, lifestyle factors such as smoking, sleep disorders, and metabolic health are identified as significant adjunctive modulators of disease progression.
conclusionsTargeted therapies, specifically JAK inhibitors, have transformed the prognosis for severe AA. However, high costs, relapse post-discontinuation, and long-term safety profiles necessitate careful patient selection. Future management must integrate advanced pharmacotherapy with holistic lifestyle interventions and personalized medicine based on prognostic biomarkers.
Indexed as
Identifiers
42176145What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.